Navigation Links
Sunitinib a Promising Agent for Treatment of Renal Cell Cancer

Sunitinib has been found to be an effective agent for treating metastatic renal cell cancer, a disease for which no effective treatment options are available so far//.

There is an urgent need for more active agents for the treatment of metastatic (spread of cancer from point of origin to another part of the body) renal cell carcinoma (RCC). The 5-year survival rate for metastatic RCC is estimated to be less than 10 percent, according to background information in the article. RCC is highly resistant to chemotherapy, and only a limited subset of patients (20 percent or less) benefit from cytokine (proteins from the immune system) therapy (high-dose interleukin-2 [IL-2] and/or interferon-alfa). Overall median survival following progression after cytokine therapy is approximately 10 to 13 months, and no effective treatment is available for patients whose disease progresses after an initial response, or who do not respond to cytokine therapy.

A better understanding of the genetic abnormalities associated with clear-cell RCC has helped identify new targets for therapy, and subsequently the development of a new therapy, the oral medication sunitinib, which had positive results in an initial study.

Robert J. Motzer, M.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted a multicenter phase 2 trial to confirm the antitumor efficacy of sunitinib in 106 patients with metastatic clear-cell RCC whose disease was refractory (unresponsive) to 1 prior cytokine therapy.

Patients were enrolled between February and November 2004, with follow-up continuing until disease progression, unacceptable toxicity, or withdrawal of consent. Patients received repeated 6-week cycles of sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.

“The results of this trial confirm that sunitinib given once daily according to a 4 weeks on/2 weeks off schedule has sub stantial antitumor effects against metastatic clear-cell RCC. Of the 105 evaluable patients, 36 patients achieved partial response (34 percent), and a median progression-free survival of 8.3 months as evaluated by the independent third-party core imaging laboratory (resulting in a value considerably longer than expected in this clinical setting),” the authors write.

The most common adverse events experienced by patients were fatigue 30 (28 percent) and diarrhea 21 (20 percent).

(Source: Newswise)
'"/>




Related medicine news :

1. Promising Treatment for Diabetes
2. Life after Bypass not so Promising for Women.
3. Promising cure for West Nile Virus
4. Deadly Diarrhoea Vaccine – Trail Results Promising
5. Novartis MS Drug Shows Promising Results
6. Promising Care Model For Bipolar Disorder
7. A Promising New Vaccination Strategy for Late-Stage Melanoma
8. Promising Brain Tumor Treatment In The Offing
9. Sea Creatures Toxin Could Lead to Promising Cancer Treatment
10. Vaccine Promising Against Hepatitis E
11. Groups Join Forces to Fund Promising Lung Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2018)... ... 15, 2018 , ... On July 30, more than 250 people attended Calvary ... Country Club in Westchester County. The event raised over $300,000 for Calvary programs and ... event included a performance by mentalist and comedian Eric Dittelman, a live auction, silent ...
(Date:8/14/2018)... ... August 14, 2018 , ... Smile Brands Inc. ... affiliated offices across 16 states, is pleased to announce its latest partnership with ... Brands will provide full-service administrative support to the practice, including; purchasing, payroll, accounting, ...
(Date:8/11/2018)... ... August 10, 2018 , ... TopConsumerReviews.com ... Relief. , What is gout? This painful, persistent condition originates in the liver ... high levels of uric acid. Other contributing factors may be medication side effects, ...
(Date:8/9/2018)... ... 2018 , ... Thousands of US women with FDA-approved silicone ... from The American Society of Plastic Surgeons (ASPS), The American Society for Aesthetic ... As an MRI is recommended by FDA after the first three years then ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... as an Operating Partner and will have an exclusive relationship with the firm. ... the firm’s strategic planning, human capital sourcing, and deal origination, evaluation and diligence. ...
Breaking Medicine News(10 mins):
(Date:8/2/2018)... ... August 02, 2018 , ... ... smile for custom crown lengthening treatment at his Eden Prairie, MN ... and an unsteady self-conscious. Using decades of experience, Dr. Sanchez is excited to ...
(Date:8/2/2018)... ... 2018 , ... Clay and Associates DDS, PLC is excited to welcome Dr. ... Dr. John Clay and Dr. Shaun O’Neill as an associate dentist to the practice. ... their patients' dental hygiene, encapsulates the core values of the professional dental team at ...
(Date:8/2/2018)... DUBLIN, Ohio (PRWEB) , ... ... ... , a single collaboration platform with customer relationship management (CRM), patient experience ... accreditation through the DirectTrust Accreditation Program for Health Information Service Providers (HISPs). ...
Breaking Medicine Technology: